@article {SMITH4489, author = {ALAN D. SMITH and MATHEW TRUONG and ROB BRISTOW and PAUL YIP and MICHAEL F. MILOSEVIC and ANTHONY M. JOSHUA}, title = {The Utility of Serum CA9 for Prognostication in Prostate Cancer}, volume = {36}, number = {9}, pages = {4489--4492}, year = {2016}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: Carbonic anhydrase IX (CA9) catalyses the interconversion of carbon dioxide to carbonic acid and bicarbonate and is considered a putative biomarker of tumour hypoxia. We set out to evaluate the prognostic significance of CA9 in prostate cancer. Patients and Methods: Plasma samples were assessed from 68 men with high-risk localised prostate cancer treated with radical prostatectomy (RP) or radiotherapy (RT), and 20 men with castration-resistant prostate cancer (CRPC) treated with docetaxel chemotherapy between 2010 and 2012 at the Princess Margaret Cancer Centre, Canada. Results: Of the 68 patients with high-risk localised prostate cancer, 57 underwent RP and 11 underwent RT. Baseline CA9 was not associated with recurrence or prostate-specific antigen in either group (p=0.98 and 0.20, respectively). CA9 levels before chemotherapy correlated with overall survival (r=-0.37; two-sided p=0.11). Conclusion: Baseline CA9 in men with CRPC may portend a more aggressive prostate cancer phenotype with poorer survival.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/36/9/4489}, eprint = {https://ar.iiarjournals.org/content/36/9/4489.full.pdf}, journal = {Anticancer Research} }